News

Video

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

Author(s):

Constantine S. Tam, MD, MBBS

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD
Naval G. Daver, MD,
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Andrew Hantel, MD
Related Content
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Leonard Mazur, CEO, Citius Pharma, Citius Oncology
September 6th 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Reid W. Merryman, MD
September 5th 2024

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

Rayne Helen Rouce, MD, BS, Baylor College of Medicine
September 4th 2024

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL